86,746 research outputs found
Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA
No full textHow i treat malignant pleural mesothelioma
No full textMalignant pleural mesothelioma is a rare and aggressive malignancy mostly associated with occupational asbestos exposure. Prognosis is poor and only highly selected patients may benefit from aggressive surgical management, also as part of a multimodal approach. In advanced disease, the combination of pemetrexed and platinum remains the only established treatment, while efficacy evidence of second line chemotherapy is lacking. Thus, a deeper knowledge of biology of the disease and more effective treatments are urgently needed. Refer to specialised centres with multidisciplinary expertise is mandatory, as well as inclusion of patients in clinical trials is advisable whenever possible. In all stages of disease focus on symptoms control is paramount
Potentiation of the antitumor acitivity of bortezomib, a proteasome inhibitor, by the combination with EGFR inhibitors in human cancer cell lines.
No full text
Learning time-varying Gaussian quantum lossy channels
No full textTime-varying quantum channels are essential for modeling realistic quantum systems with evolving noise properties. Here, we consider Gaussian lossy channels varying from one use to another and we employ neural networks to classify, regress, and forecast the behavior of these channels from their Choi-Jamiołkowski states. The networks achieve at least 87% of accuracy in distinguishing between non-Markovian, Markovian, memoryless, compound, and deterministic channels. In regression tasks, the model accurately reconstructs the loss parameter sequences, and in forecasting, it predicts future values, with improved performance as the memory parameter approaches 1 for Markovian channels. These results demonstrate the potential of neural networks in characterizing and predicting the dynamics of quantum channels
Delivery optimization of erlotinib according to toxicity: may clinical practice go beyond research?
No full textNon applicabil
51PD Effect of MEK inhibition on PDL1 and and on cytokinesproduction profilein NSCLC cell lines and in human lymphocites
No full text
- …
